Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Personalizing medicine for cancer: the next decade

Nature Reviews Drug Discovery volume 9, pages 343–344 (2010)Cite this article

Subjects

Abstract

An important outcome of the focus on the human genome in the past decade has been the understanding that cancer is largely a disease of aberrant cell signalling. The development of drugs that target the results of genetic defects in selected patients with cancer has led to some important treatment advances, but there remain major challenges to realizing the full potential of genomic medicine in oncology.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Raghavan, D. An essay on rearranging the deck chairs: what's wrong with the cancer trials system? Clin. Cancer Res. 12, 1949–1950 (2006).

    Article  PubMed  Google Scholar 

  2. Kuzrock, R. et al. Project Zero Delay: a process for accelerating the activation of cancer clinical trials. J. Clin. Oncol. 27, 4433–4440 (2009).

    Article  Google Scholar 

  3. Kattan, M. W. The many uses of cancer prediction tools. Semin. Oncol. 37, 20–22 (2010).

    Article  PubMed  Google Scholar 

  4. Hamburg, M. A. & Sharfstein, J. M. The FDA as a public health agency. N. Engl. J. Med. 360, 2493–2495 (2009).

    Article  CAS  Google Scholar 

  5. Institute of Medicine of the National Acadamies. Innovations in Service Delivery in the Age of Genomics. National Academy of Sciences website [online], (2009).

Download references

Author information

Authors and Affiliations

  1. Ernest C. Borden, M.D., is Deputy Director of, and Derek Raghavan M.D., Ph.D., is Chair at the Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. bordene@ccf.org; raghavd@ccf.org,

    Ernest C. Borden & Derek Raghavan

  2. raghavd@ccf.org,

    Ernest C. Borden & Derek Raghavan

Authors
  1. Ernest C. Borden
    View author publications

    Search author on:PubMed Google Scholar

  2. Derek Raghavan
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borden, E., Raghavan, D. Personalizing medicine for cancer: the next decade. Nat Rev Drug Discov 9, 343–344 (2010). https://doi.org/10.1038/nrd3168

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd3168

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing